Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.9385
-0.0148 (-1.55%)
At close: Sep 12, 2025, 4:00 PM EDT
0.9204
-0.0181 (-1.93%)
After-hours: Sep 12, 2025, 4:53 PM EDT
Cytosorbents Revenue
Cytosorbents had revenue of $9.62M in the quarter ending June 30, 2025, with 8.76% growth. This brings the company's revenue in the last twelve months to $36.11M, up 20.18% year-over-year. In the year 2024, Cytosorbents had annual revenue of $35.59M with 14.51% growth.
Revenue (ttm)
$36.11M
Revenue Growth
+20.18%
P/S Ratio
1.51
Revenue / Employee
$242,332
Employees
149
Market Cap
58.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.59M | 4.51M | 14.51% |
| Dec 31, 2023 | 31.08M | -3.60M | -10.39% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CTSO News
- 6 days ago - CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day - PRNewsWire
- 9 days ago - CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 25 days ago - CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR - PRNewsWire
- 5 weeks ago - Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 6 weeks ago - CytoSorbents Leads a New Era in Sepsis Treatment - PRNewsWire
- 6 weeks ago - CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 2 months ago - CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR - PRNewsWire